ERBB2 and cancer: Surprisingly, a low concentration of doxorubicin induces epithelial-to-mesenchymal transition (EMT) followed by an increase instead of inhibition of cancer metastasis.18,19 Therefore, brazilin has potential to be developed as a co-chemotherapeutic agent to counter doxorubicin-induced migration and invasion on HER2-overexpressing cancer cells.